Eidos Therapeutics Inc (EIDX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Neil Kumar
Employees:
24
101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO, CA 94104
650-391-9740

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR).

Data derived from most recent annual or quarterly report
Market Cap 4.749 Billion Shares Outstanding38.862 Million Avg 30-day Volume 113.98 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.14
Price to Revenue0.0 Debt to Equity0.1362 EBITDA-58.394 Million
Price to Book Value15.789 Operating Margin0.0 Enterprise Value1.809 Billion
Current Ratio11.105 EPS Growth-3.357 Quick Ratio10.672
1 Yr BETA 1.0647 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-243.8781 Altman Z-Score28.289 Free Cash Flow to Firm -35.71 Million
View SEC Filings from EIDX instead.

View recent insider trading info

Eidos Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EIDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EIDX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2021-01-28 by FOX JONATHAN C
  • 4: filed on 2021-01-28 by ROHLEN DOUGLAS
  • 4: filed on 2021-01-28 by VALLE FRANCO
  • 4: filed on 2021-01-28 by TURTLE CAMERON
  • 4: filed on 2021-01-28 by SATVAT ALI J.
  • 4: filed on 2021-01-28 by LIS WILLIAM
  • 4: filed on 2021-01-28 by HOOPER SUZANNE SAWOCHKA
  • 4: filed on 2021-01-28 by SINHA UMA
  • 4: filed on 2021-01-26 by BridgeBio Pharma, Inc.
  • 4: filed on 2021-01-15 by SINHA UMA

    • Events (8k)

  • 8-K: filed on 2021-01-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-20:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-12:
    Item 8.01: Other Events
  • 8-K: filed on 2020-10-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-29:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-03-24:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ROHLEN DOUGLAS

    • Director
    		 No longer subject to file 2021-01-26 0

    HOOPER SUZANNE SAWOCHKA

    • Director
    		 No longer subject to file 2021-01-26 0

    LIS WILLIAM

    • Director
    		 No longer subject to file 2021-01-26 0

    SATVAT ALI J.

    • Director
    		 No longer subject to file 2021-01-26 0

    FOX JONATHAN C SEE REMARKS

    • Officer
    		 No longer subject to file 2021-01-26 0

    VALLE FRANCO SENIOR VICE PRESIDENT, FINANCE

    • Officer
    		 No longer subject to file 2021-01-26 0

    SINHA UMA CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2021-01-26 0

    BRIDGEBIO PHARMA, INC.

    • 10% Owner
    		 1,000 2021-01-26 0

    TURTLE CAMERON CHIEF BUSINESS OFFICER

    • Officer
    		 No longer subject to file 2021-01-26 0

    AGUIAR ERIC

    • Director
    		 0 2020-05-27 0

    SHAH RAJEEV M.

    • Director
    		 0 2020-05-27 0

    SIU CHRISTINE CFO AND SECRETARY

    • Officer
    		 36,470 2019-12-09 0

    KUMAR NEIL CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    • 10% Owner
    		 24,575,501 2019-07-03 0

    LIS WILLIAM

    LIS WILLIAM

    • Director
    		 0 2018-12-04 0

    RA CAPITAL MANAGEMENT, LLC

    RA CAPITAL HEALTHCARE FUND LP

    KOLCHINSKY PETER

    • Director
    • 10% Owner
    		 2,162,671 2018-06-22 0

    HUH HOYOUNG

    • Director
    		 0 2018-06-22 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments